Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-U00096 |
Brand: | MCE |
CAS: | 916918-84-8 |
MDL | - |
---|---|
Molecular Weight | 417.97 |
Molecular Formula | C24H32ClNO3 |
SMILES | O=C(OC1=CC=C(C(C2(O)CCCCC2)CN(C)C)C=C1)C3=CC=C(C)C=C3.[H]Cl |
Ansofaxine hydrochloride (LY03005; LPM570065) is a triple reuptake inhibitor; inhibits serotonin , dopamine and norepinephrine reuptake with IC 50 values of 723, 491 and 763 nM, respectively.
serotonin 723 nM (IC 50 ) |
Dopamine Receptor 491 nM (IC 50 ) |
Ansofaxine rapidly penetrates the rat striatum, converts into desvenlafaxine and exhibits larger total exposure compared with the administration of desvenlafaxine. Acute and chronic administration of oral suspension of ansofaxine increases the 5-HT, dopamine and norepinephrine levels more than the relative administration of desvenlafaxine. Unlike desvenlafaxine, acute administration of an intravenous ansofaxine solution does not induce the undesirable 90% decrease in extracellular 5-HT levels. The acute administration of ansofaxine shows a capped increase in extracellular 5-HT levels when combined with WAY-100635. Acute and chronic administration of ansofaxine reduces the immobility time more than the relative administration of desvenlafaxine [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT02988024 | Luye Pharma Group Ltd. |
Major Depression
|
December 7, 2016 | Phase 1 |
NCT04853407 | Luye Pharma Group Ltd. |
Major Depressive Disorder (MDD)
|
December 5, 2018 | Phase 3 |
NCT02271412 | Luye Pharma Group Ltd. |
Major Depressive Disorder, Recurrent, Unspecified
|
October 2014 | Phase 1 |
NCT03785652 | Luye Pharma Group Ltd.|Shandong Luye Pharmaceutical Co., Ltd. |
Major Depressive Disorder
|
October 9, 2015 | Phase 1 |
NCT02055300 | Luye Pharma Group Ltd. |
Major Depressive Disorder
|
February 2014 | Phase 1 |
NCT03822065 | Luye Pharma Group Ltd. |
Major Depressive Disorder
|
January 16, 2019 | Phase 1 |
NCT03733574 | Luye Pharma Group Ltd. |
Major Depressive Disorder
|
June 19, 2018 | Phase 1 |
NCT03357796 | Luye Pharma Group Ltd. |
Major Depressive Disorder
|
November 27, 2017 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 31.25 mg/mL ( 74.77 mM ; Need ultrasonic)
H 2 O : 6.67 mg/mL ( 15.96 mM ; ultrasonic and warming and heat to 60°C)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.3925 mL | 11.9626 mL | 23.9252 mL |
5 mM | 0.4785 mL | 2.3925 mL | 4.7850 mL |
10 mM | 0.2393 mL | 1.1963 mL | 2.3925 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.